Stock & Company Details
Jazz Pharmaceuticals plc $JAZZ
Price:
N/A
N/A
65M
$14B
52 Week High:
N/A
10 Day Average Volume:
N/A
15.21
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
JAZZ technical indicators
Latest Jazz Pharmaceuticals plc (JAZZ) indicator readings as of 2026-10-09.
JAZZ's 14-day RSI is 26.9, in oversold territory. At $218.42 it is trading 2.3% above its 200-day moving average of $213.42, and below its 50-day average of $244.39. Price sits below the lower Bollinger Band ($222.38 to $249.25). ADX reads 28.3, indicating a trending market.
JAZZ backtested strategy results
How 4 rule-based strategies performed on Jazz Pharmaceuticals plc (JAZZ) over recent history, last backtested 2026-09-05. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -30.3% | 29% | 7 | -36.4% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +39.0% | 31% | 29 | -47.0% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -6.0% | 47% | 30 | -44.2% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +58.9% | 77% | 22 | -24.4% |
Overview
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Finance Bot
Ask your questions
Start by typing a question below.
